Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTEUS: Apalutamide plus ADT in high-risk localized or locally advanced prostate cancer undergoing radical prostatectomy
jRCT2080224707Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in prostate adenocarcinoma and prostate cancer (PCa) comparing Apalutamide + ADT with Placebo + ADT (2 arms). Started Jun 2019; status: completed.
02
Drugs
apalutamide
03
Conditions
prostate adenocarcinomaprostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2080224707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224707.